Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1995
Business Overview: ImmuCell is a biotechnology company focused on developing passive antibody products to prevent gastrointestinal diseases. Key products include First Defense and the Kamar Heatmount Detector. The company relies on product sales, grant income, and collaborative research revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1995 | Six Months Ended June 30, 1994 |
|---|---|---|
| Total Revenues | $2,632,224 | $2,266,532 |
| Net Loss | $(10,981) | $(62,048) |
| Net Loss Per Share | $0.00 | $(0.02) |
| Cash and Cash Equivalents (Ending) | $882,631 | $1,664,979 |
| Short-term Investments | $449,276 | $0 |
| Total Current Assets | $2,338,110 | $2,296,902 |
| Total Current Liabilities | $586,973 | $569,377 |
| Long-Term Debt | $568,900 | $629,767 |
| Net Working Capital | $1,751,137 | $1,727,525 |
| Product Gross Margin | 55% | 49% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% ($366,000) year-over-year for the six-month period, driven primarily by an 18% increase in product sales. However, collaborative research revenue dropped to zero in 1995 after Univax Biologics terminated its sponsorship in May 1995.
- Profitability Improvement: Net loss narrowed significantly from $62,048 in the prior year to $10,981 in the current period. This improvement was aided by grant income of $248,630 and improved gross margins on product sales (up to 55% from 49%).
- Expense Increases: Research and development (R&D) expenses rose 34% to $856,122 due to clinical trial costs and development of new antibody products. General and administrative expenses increased by $44,000.
- Liquidity Shift: While cash and cash equivalents decreased by $412,615, the company deployed $449,276 into short-term investments. Total liquid assets (cash + short-term investments) increased slightly to $1,331,907.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur further operating losses as it aggressively invests in R&D to develop products preventing gastrointestinal diseases. The company believes it has sufficient capital to fund operations for the next twelve months.
- Grant Funding: The company secured three NIAID SBIR grants totaling $1,054,000 to fund vaccine and antibody development. Approximately 66% of these funds will cover internal R&D.
- Strategic Shift: Following the termination of the Univax partnership, ImmuCell reacquired marketing rights to CryptoGAM and is now funding its Phase I/II trials internally.
- Contingency: To maintain an exclusive license for a milk whey purification machine, the company must purchase a unit valued at approximately $450,000. The deadline was extended to May 1996, and the company does not intend to use current cash for this purchase, requiring outside funding if the acquisition proceeds.
- Risks: Continued reliance on grant funding and the need for external financing for future product development and potential equipment purchases.
Investor Verification Checklist
- Grant Sustainability: Verify the status and renewal likelihood of the three NIAID SBIR grants totaling $1,054,000, which are critical to offsetting R&D costs.
- Univax Termination Impact: Assess the financial impact of funding the CryptoGAM Phase I/II trials internally after the loss of the $210,000 milestone payment and ongoing collaboration revenue.
- Capital Requirements: Confirm the company's ability to secure external funding for the $450,000 purification machine purchase by May 1996 if the exclusive license is to be maintained.
- Cash Burn Rate: Monitor the net cash used in operating activities ($102,281 provided in 1995 vs. $162,150 in 1994) and investing activities to ensure liquidity remains sufficient for the projected 12-month runway.
- Product Sales Concentration: Note that 86% of product sales are derived from two products (First Defense and Kamar Heatmount Detector); verify the stability of these revenue streams.